NASDAQ: $SMMT A Breakthrough in Oncology Recent findings published in The Lancet have shed light on the promising results of the HARMONI Phase III clinical trial. The study evaluates the efficacy and safety of ivonescimab, a novel bispecific antibody, when combined with chemotherapy for the treatment of patients with locally advanced or metastatic non-squamous non-small…